The Filings Report

Pfizer Inc.

PFENYSECIK 78003Healthcare / Drug Manufacturersfiscal year ends December73 quarters since 2008

Revenue, Q2 FY2026
$15.0B
+2.6% on Q2 FY2025
Net income
−$248M
−108.5% on Q2 FY2025
Free cash flow
$302M
+125.2% on Q2 FY2025
Diluted EPS
$-0.04
−107.8% on Q2 FY2025
Revenue, TTM
$63.7B
trailing four quarters
Net margin, TTM
6.8%
net income $4.3B
Free cash flow, TTM
$11.0B
$13.4B less $2.4B capex
Cash and equivalents
$976M
long-term debt $60.5B, Jun 28, 2026
Shares, 12-month change
+0.3%
5.70B shares, Jun 28, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$174.0B
at the close, buybacks

Latest quarter Q2 FY2026, filed August 4, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q2 FY2026, the quarter ended June 28, 2026, Pfizer Inc. reported revenue of $15.0B, +2.6% on Q2 FY2025, and net loss of $248M (−108.5%). Free cash flow, operating cash flow less capital expenditures, was $302M ($835M less $533M). Diluted earnings per share were $-0.04.

The last 16 quarters

Q3 FY2022 to Q2 FY2026, through the filing of August 4, 2026.

Revenue and net incomeRevenueNet income
−$10B$0$10B$20B$30BQ3'22, Revenue: $22.6BQ3'22, Net income: $8.6BQ3'22Q4'22, Revenue: $25.1BQ4'22, Net income: $5.0BQ4'22Q1'23, Revenue: $18.5BQ1'23, Net income: $5.5BQ1'23Q2'23, Revenue: $13.0BQ2'23, Net income: $2.3BQ2'23Q3'23, Revenue: $13.5BQ3'23, Net income: −$2.4BQ3'23Q4'23, Revenue: $14.6BQ4'23, Net income: −$3.4BQ4'23Q1'24, Revenue: $14.9BQ1'24, Net income: $3.1BQ1'24Q2'24, Revenue: $13.3BQ2'24, Net income: $41MQ2'24Q3'24, Revenue: $17.7BQ3'24, Net income: $4.5BQ3'24Q4'24, Revenue: $17.8BQ4'24, Net income: $410MQ4'24Q1'25, Revenue: $13.7BQ1'25, Net income: $3.0BQ1'25Q2'25, Revenue: $14.7BQ2'25, Net income: $2.9BQ2'25Q3'25, Revenue: $16.7BQ3'25, Net income: $3.5BQ3'25Q4'25, Revenue: $17.6BQ4'25, Net income: −$1.6BQ4'25Q1'26, Revenue: $14.5BQ1'26, Net income: $2.7BQ1'26Q2'26, Revenue: $15.0BQ2'26, Net income: −$248MQ2'26−$10B$0$10B$20B$30BQ3'22, Revenue: $22.6BQ3'22, Net income: $8.6BQ4'22, Revenue: $25.1BQ4'22, Net income: $5.0BQ4'22Q1'23, Revenue: $18.5BQ1'23, Net income: $5.5BQ2'23, Revenue: $13.0BQ2'23, Net income: $2.3BQ2'23Q3'23, Revenue: $13.5BQ3'23, Net income: −$2.4BQ4'23, Revenue: $14.6BQ4'23, Net income: −$3.4BQ4'23Q1'24, Revenue: $14.9BQ1'24, Net income: $3.1BQ2'24, Revenue: $13.3BQ2'24, Net income: $41MQ2'24Q3'24, Revenue: $17.7BQ3'24, Net income: $4.5BQ4'24, Revenue: $17.8BQ4'24, Net income: $410MQ4'24Q1'25, Revenue: $13.7BQ1'25, Net income: $3.0BQ2'25, Revenue: $14.7BQ2'25, Net income: $2.9BQ2'25Q3'25, Revenue: $16.7BQ3'25, Net income: $3.5BQ4'25, Revenue: $17.6BQ4'25, Net income: −$1.6BQ4'25Q1'26, Revenue: $14.5BQ1'26, Net income: $2.7BQ2'26, Revenue: $15.0BQ2'26, Net income: −$248MQ2'26

Net income losses drawn in red.

Free cash flow
−$3B$0$3B$5B$8B$10BQ3'22, Free cash flow: $5.1BQ3'22Q4'22, Free cash flow: $7.6BQ4'22Q1'23, Free cash flow: $73MQ1'23Q2'23, Free cash flow: −$2.1BQ2'23Q3'23, Free cash flow: $2.6BQ3'23Q4'23, Free cash flow: $4.2BQ4'23Q1'24, Free cash flow: $386MQ1'24Q2'24, Free cash flow: −$2.4BQ2'24Q3'24, Free cash flow: $6.1BQ3'24Q4'24, Free cash flow: $5.8BQ4'24Q1'25, Free cash flow: $1.8BQ1'25Q2'25, Free cash flow: −$1.2BQ2'25Q3'25, Free cash flow: $4.0BQ3'25Q4'25, Free cash flow: $4.5BQ4'25Q1'26, Free cash flow: $2.2BQ1'26Q2'26, Free cash flow: $302MQ2'26−$3B$0$3B$5B$8B$10BQ3'22, Free cash flow: $5.1BQ4'22, Free cash flow: $7.6BQ4'22Q1'23, Free cash flow: $73MQ2'23, Free cash flow: −$2.1BQ2'23Q3'23, Free cash flow: $2.6BQ4'23, Free cash flow: $4.2BQ4'23Q1'24, Free cash flow: $386MQ2'24, Free cash flow: −$2.4BQ2'24Q3'24, Free cash flow: $6.1BQ4'24, Free cash flow: $5.8BQ4'24Q1'25, Free cash flow: $1.8BQ2'25, Free cash flow: −$1.2BQ2'25Q3'25, Free cash flow: $4.0BQ4'25, Free cash flow: $4.5BQ4'25Q1'26, Free cash flow: $2.2BQ2'26, Free cash flow: $302MQ2'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$20B$40B$60B$80BQ3'22, Cash and equivalents: $1.3BQ3'22, Long-term debt: $32.6BQ3'22Q4'22, Cash and equivalents: $416MQ4'22, Long-term debt: $32.9BQ4'22Q1'23, Cash and equivalents: $2.2BQ1'23, Long-term debt: $31.7BQ1'23Q2'23, Cash and equivalents: $2.6BQ2'23, Long-term debt: $61.4BQ2'23Q3'23, Cash and equivalents: $3.1BQ3'23, Long-term debt: $61.0BQ3'23Q4'23, Cash and equivalents: $2.9BQ4'23, Long-term debt: $61.5BQ4'23Q1'24, Cash and equivalents: $719MQ1'24, Long-term debt: $61.3BQ1'24Q2'24, Cash and equivalents: $1.1BQ2'24, Long-term debt: $57.5BQ2'24Q3'24, Cash and equivalents: $1.1BQ3'24, Long-term debt: $58.0BQ3'24Q4'24, Cash and equivalents: $1.0BQ4'24, Long-term debt: $57.4BQ4'24Q1'25, Cash and equivalents: $1.4BQ1'25, Long-term debt: $57.6BQ1'25Q2'25, Cash and equivalents: $1.6BQ2'25, Long-term debt: $57.5BQ2'25Q3'25, Cash and equivalents: $1.3BQ3'25, Long-term debt: $57.4BQ3'25Q4'25, Cash and equivalents: $1.1BQ4'25, Long-term debt: $61.6BQ4'25Q1'26, Cash and equivalents: $1.7BQ1'26, Long-term debt: $60.6BQ1'26Q2'26, Cash and equivalents: $976MQ2'26, Long-term debt: $60.5BQ2'26$0$20B$40B$60B$80BQ3'22, Cash and equivalents: $1.3BQ3'22, Long-term debt: $32.6BQ4'22, Cash and equivalents: $416MQ4'22, Long-term debt: $32.9BQ4'22Q1'23, Cash and equivalents: $2.2BQ1'23, Long-term debt: $31.7BQ2'23, Cash and equivalents: $2.6BQ2'23, Long-term debt: $61.4BQ2'23Q3'23, Cash and equivalents: $3.1BQ3'23, Long-term debt: $61.0BQ4'23, Cash and equivalents: $2.9BQ4'23, Long-term debt: $61.5BQ4'23Q1'24, Cash and equivalents: $719MQ1'24, Long-term debt: $61.3BQ2'24, Cash and equivalents: $1.1BQ2'24, Long-term debt: $57.5BQ2'24Q3'24, Cash and equivalents: $1.1BQ3'24, Long-term debt: $58.0BQ4'24, Cash and equivalents: $1.0BQ4'24, Long-term debt: $57.4BQ4'24Q1'25, Cash and equivalents: $1.4BQ1'25, Long-term debt: $57.6BQ2'25, Cash and equivalents: $1.6BQ2'25, Long-term debt: $57.5BQ2'25Q3'25, Cash and equivalents: $1.3BQ3'25, Long-term debt: $57.4BQ4'25, Cash and equivalents: $1.1BQ4'25, Long-term debt: $61.6BQ4'25Q1'26, Cash and equivalents: $1.7BQ1'26, Long-term debt: $60.6BQ2'26, Cash and equivalents: $976MQ2'26, Long-term debt: $60.5BQ2'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q2 FY2026 filed August 4, 2026.

Pfizer Inc. income statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 28, 2026filed Aug 4, 2026Q1 FY2026ended Mar 29, 2026filed May 5, 2026Q4 FY2025ended Dec 31, 2025filed Feb 26, 2026Q3 FY2025ended Sep 28, 2025filed Nov 4, 2025Q2 FY2025ended Jun 29, 2025filed Aug 5, 2025Q1 FY2025ended Mar 30, 2025filed May 5, 2025Q4 FY2024ended Dec 31, 2024filed Feb 27, 2025Q3 FY2024ended Sep 29, 2024filed Nov 4, 2024YoYQ2 FY2026vs Q2 FY2025
Revenue15,03414,45117,55716,65414,65313,71517,76317,702+2.6%
Cost of revenue4,0923,5485,2724,1723,7782,8455,9095,263+8.3%
Gross profit—————————
Research and development—————————
Selling, general and administrative3,4112,9614,1623,1863,4153,0314,2743,244−0.1%
Operating income—————————
Other income (expense)(3,716)(861)(4,514)(517)(739)(953)(2,358)(243)−402.8%
Pretax income(653)3,170(1,642)3,3343,0442,785(10)4,715−121.5%
Income tax(407)461(2)(216)141(189)(421)234−388.7%
Net income(248)2,687(1,648)3,5412,9102,9674104,465−108.5%
Diluted EPS ($)(0.04)0.47—0.620.510.52—0.78−107.8%
Diluted shares (millions)5,6995,731—5,7145,7065,710—5,705—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q2 FY2026 filed August 4, 2026.

Pfizer Inc. balance sheet, quarterly
Millions of dollarsQ2 FY2026ended Jun 28, 2026filed Aug 4, 2026Q1 FY2026ended Mar 29, 2026filed May 5, 2026Q4 FY2025ended Dec 31, 2025filed Feb 26, 2026Q3 FY2025ended Sep 28, 2025filed Nov 4, 2025Q2 FY2025ended Jun 29, 2025filed Aug 5, 2025Q1 FY2025ended Mar 30, 2025filed May 5, 2025Q4 FY2024ended Dec 31, 2024filed Feb 27, 2025Q3 FY2024ended Sep 29, 2024filed Nov 4, 2024YoYQ2 FY2026vs Q2 FY2025
Cash and equivalents9761,7031,1421,3431,6381,4301,0431,092−40.4%
Short-term investments7,2818,1899,18310,1239,52513,95210,8816,849−23.6%
Total current assets41,35842,82242,89846,92443,70345,86150,35843,223−5.4%
Total assets201,131207,618208,160208,731206,095208,028213,396219,476−2.4%
Total current liabilities32,64634,34836,98436,59637,72636,45242,99543,211−13.5%
Long-term debt60,49560,56561,64157,40957,50257,63957,40558,002+5.2%
Total liabilities115,639117,214121,385115,635117,083117,391124,899126,918−1.2%
Stockholders’ equity85,19090,10186,47692,80188,69590,33888,20392,286−4.0%
Shares outstanding (millions)5,7005,6995,6865,6865,6865,6855,6675,667—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q2 FY2026 filed August 4, 2026.

Pfizer Inc. cash flow statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 28, 2026filed Aug 4, 2026Q1 FY2026ended Mar 29, 2026filed May 5, 2026Q4 FY2025ended Dec 31, 2025filed Feb 26, 2026Q3 FY2025ended Sep 28, 2025filed Nov 4, 2025Q2 FY2025ended Jun 29, 2025filed Aug 5, 2025Q1 FY2025ended Mar 30, 2025filed May 5, 2025Q4 FY2024ended Dec 31, 2024filed Feb 27, 2025Q3 FY2024ended Sep 29, 2024filed Nov 4, 2024YoYQ2 FY2026vs Q2 FY2025
Operating cash flow8352,6155,3484,603(582)2,3356,7216,714+243.5%
Capital expenditures533436845602618564917651−13.8%
Free cash flow (CFO − capex)3022,1794,5034,001(1,200)1,7715,8046,063+125.2%
Depreciation and amortization1,6221,6131,6871,6621,6251,6181,7911,755−0.2%
Share repurchases—————————
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 26, 2026.

Income statement

Pfizer Inc. income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 26, 2026FY2024ended Dec 31, 2024filed Feb 27, 2025FY2023ended Dec 31, 2023filed Feb 22, 2024FY2022ended Dec 31, 2022filed Feb 23, 2023FY2021ended Dec 31, 2021filed Feb 24, 2022FY2020ended Dec 31, 2020filed Feb 25, 2021FY2019ended Dec 31, 2019filed Feb 27, 2020FY2018ended Dec 31, 2018filed Feb 28, 2019FY2017ended Dec 31, 2017filed Feb 22, 2018FY2016ended Dec 31, 2016filed Feb 23, 2017FY2015ended Dec 31, 2015filed Feb 29, 2016FY2014ended Dec 31, 2014filed Feb 27, 2015FY2013ended Dec 31, 2013filed Feb 28, 2014FY2012ended Dec 31, 2012filed Feb 28, 2013FY2011ended Dec 31, 2011filed Feb 28, 2012FY2010ended Dec 31, 2010filed Feb 28, 2011FY2009ended Dec 31, 2009filed Feb 26, 2010FY2008ended Dec 31, 2008filed Aug 6, 2009FY2007ended Dec 31, 2007filed Aug 6, 2009
Revenue62,57963,62759,553101,17573,63641,65140,90540,82552,54652,824——51,58454,65761,03565,16549,26948,29648,418
Cost of revenue16,06717,85124,95434,34430,8218,4848,0548,98711,22812,322——9,5869,82112,50014,7888,4598,11211,239
Gross profit———————————————————
Research and development———————————————————
Selling, general and administrative13,79414,73014,77113,67712,70311,59712,72612,61214,80414,84414,80914,09714,35515,17117,58118,97314,75214,53715,626
Operating income———————————————————
Other income (expense)(6,724)(4,388)(222)(1,062)4,878(1,213)(3,497)(2,077)(1,416)(3,794)(2,860)(1,009)532(4,022)(139)147(62)(48)—
Pretax income7,5208,0231,05834,72924,3117,03611,3213,59412,3058,3518,96512,24015,71611,24211,4819,47110,6749,6949,278
Income tax(266)(28)(1,115)3,3281,852370583(266)(9,049)1,1231,9903,1204,3062,2213,6211,1532,1451,6451,023
Net income7,7718,0312,11931,37221,9799,15916,02611,15321,3087,2156,9609,13522,00314,57010,0098,2578,6358,1048,144
Diluted EPS ($)1.361.410.375.473.851.632.821.873.521.171.111.423.191.941.271.021.231.201.17
Diluted shares (millions)5,7135,7005,7095,7335,7085,6325,6755,9776,0586,1596,2576,4246,8957,5087,8708,0747,0456,7506,939

Balance sheet

Pfizer Inc. balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 26, 2026FY2024ended Dec 31, 2024filed Feb 27, 2025FY2023ended Dec 31, 2023filed Feb 22, 2024FY2022ended Dec 31, 2022filed Feb 23, 2023FY2021ended Dec 31, 2021filed Feb 24, 2022FY2020ended Dec 31, 2020filed Feb 25, 2021FY2019ended Dec 31, 2019filed Feb 27, 2020FY2018ended Dec 31, 2018filed Feb 28, 2019FY2017ended Dec 31, 2017filed Feb 22, 2018FY2016ended Dec 31, 2016filed Feb 23, 2017FY2015ended Dec 31, 2015filed Feb 29, 2016FY2014ended Dec 31, 2014filed Feb 27, 2015FY2013ended Dec 31, 2013filed Feb 28, 2014FY2012ended Dec 31, 2012filed Feb 28, 2013FY2011ended Dec 31, 2011filed Feb 28, 2012FY2010ended Dec 31, 2010filed Feb 28, 2011FY2009ended Dec 31, 2009filed Feb 26, 2010FY2008ended Dec 31, 2008filed Aug 6, 2009FY2007ended Dec 31, 2007filed Aug 6, 2009
Cash and equivalents1,1421,0432,8534161,9441,7861,1211,1391,3422,5953,6413,3432,18310,0813,1821,7351,9782,1223,406
Short-term investments9,18310,8814,40018,74322,0149,7096,68717,69418,65015,25519,64932,77930,22522,31823,27026,27723,99121,609—
Total current assets42,89850,35843,33351,25959,69335,06732,80349,92641,14138,94943,80455,59556,24464,83160,81761,01361,67043,076—
Total assets208,160213,396226,501197,205181,476154,229167,594159,422171,797171,615167,381167,566172,101185,798188,002195,014212,949111,148—
Total current liabilities36,98442,99547,79442,13842,67125,92037,30431,85830,42731,11529,39921,58723,36629,18628,90928,63637,22527,009—
Long-term debt61,64157,40561,53832,88436,19537,13335,95532,90933,53831,39828,74031,54130,46231,03634,92638,41043,1937,963—
Total liabilities121,385124,899137,213101,288104,01390,756104,14895,664100,141111,776102,38495,94495,481104,120105,381106,749122,50353,408—
Stockholders’ equity86,47688,20389,01495,66177,20163,23863,14363,40771,30859,54464,72071,30176,30781,26082,19087,81390,01457,556—
Shares outstanding (millions)5,6865,6675,6475,6195,6235,5785,5485,5525,9535,9526,1846,1296,3837,1897,5397,9958,070——

Cash flow statement

Pfizer Inc. cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 26, 2026FY2024ended Dec 31, 2024filed Feb 27, 2025FY2023ended Dec 31, 2023filed Feb 22, 2024FY2022ended Dec 31, 2022filed Feb 23, 2023FY2021ended Dec 31, 2021filed Feb 24, 2022FY2020ended Dec 31, 2020filed Feb 25, 2021FY2019ended Dec 31, 2019filed Feb 27, 2020FY2018ended Dec 31, 2018filed Feb 28, 2019FY2017ended Dec 31, 2017filed Feb 22, 2018FY2016ended Dec 31, 2016filed Feb 23, 2017FY2015ended Dec 31, 2015filed Feb 29, 2016FY2014ended Dec 31, 2014filed Feb 27, 2015FY2013ended Dec 31, 2013filed Feb 28, 2014FY2012ended Dec 31, 2012filed Feb 28, 2013FY2011ended Dec 31, 2011filed Feb 28, 2012FY2010ended Dec 31, 2010filed Feb 28, 2011FY2009ended Dec 31, 2009filed Feb 26, 2010FY2008ended Dec 31, 2008filed Aug 6, 2009FY2007ended Dec 31, 2007filed Aug 6, 2009
Operating cash flow11,70412,7448,70029,26732,58014,40312,58815,82716,80216,19214,68817,08417,68416,74620,24011,45416,58718,23813,353
Capital expenditures2,6292,9093,9073,2362,7112,2262,0461,9841,9561,8231,3971,1991,2061,3271,6601,5131,2051,7011,880
Free cash flow (CFO − capex)9,0759,8354,79326,03129,86912,17710,54213,84314,84614,36913,29115,88516,47815,41918,5809,94115,38216,53711,473
Depreciation and amortization6,5927,0136,2905,0645,1914,6815,7556,3846,2695,7575,1575,5376,3067,3948,7018,3994,7575,0905,200
Share repurchases—002,000008,86512,1985,0005,0006,1605,00016,2908,2289,0001,00005009,994
Dividends paid———————————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$3M
3 purchases by 3 insiders; officers and directors $3M
Sold, three months
$83K
1 sales by 1 insider; officers and directors $83K
Bought, twelve months
$3M
3 purchases by 3 insiders; officers and directors $3M
Sold, twelve months
$135K
2 sales by 1 insider; officers and directors $135K

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Aug 12, 2026Bourla AlbertChairman & CEO, Directoropen-market buy38,000$26.34$1M429,173Aug 12, 2026
Aug 5, 2026Damico Jennifer B.SVP & Controlleropen-market sale3,278$25.40$83K28,611Aug 6, 2026
Aug 5, 2026Blaylock Ronald EDirectoropen-market buy39,231$25.46$999K66,938Aug 5, 2026
Aug 5, 2026Buckley Mortimer JDirectoropen-market buy37,632$25.52$960K37,632Aug 5, 2026
Jun 9, 2026Damico Jennifer B.SVP & Controlleropen-market sale2,000$25.70$51K31,397Jun 10, 2026
Mar 4, 2026Damico Jennifer B.SVP & Controllertax withholding826$26.62$22K32,934Mar 5, 2026
Mar 3, 2026Damico Jennifer B.SVP & Controlleraward16,311$0.00—28,352Mar 5, 2026
Mar 3, 2026Damico Jennifer B.SVP & Controlleraward5,408$0.00—33,760Mar 5, 2026
Feb 27, 2026Damico Jennifer B.SVP & Controllertax withholding655$27.65$18K12,041Mar 3, 2026
Feb 26, 2026McDermott MichaelExecutive Vice Presidenttax withholding3,503$27.10$95K74,308Feb 27, 2026
Feb 25, 2026Sahni PayalExecutive Vice Presidenttax withholding1,083$27.09$29K81,733Feb 27, 2026
Feb 25, 2026Sahni PayalExecutive Vice Presidenttax withholding54,066$26.92$1M27,667Feb 27, 2026
Feb 25, 2026Sahni PayalExecutive Vice Presidentoption exercise56,888$33.82$2M82,816Feb 27, 2026
Feb 25, 2026Lankler Douglas MExecutive Vice Presidenttax withholding116,811$26.92$3M163,177Feb 27, 2026
Feb 25, 2026Lankler Douglas MExecutive Vice Presidenttax withholding2,198$27.09$60K279,988Feb 27, 2026
Feb 25, 2026Lankler Douglas MExecutive Vice Presidentoption exercise122,907$33.82$4M282,186Feb 27, 2026
Feb 25, 2026Damico Jennifer B.SVP & Controlleroption exercise17,558$33.82$594K29,744Feb 27, 2026
Feb 25, 2026Damico Jennifer B.SVP & Controllertax withholding16,687$26.92$449K12,696Feb 27, 2026
Feb 25, 2026Damico Jennifer B.SVP & Controllertax withholding361$27.09$10K29,383Feb 27, 2026
Feb 25, 2026Bourla AlbertChairman & CEO, Directortax withholding8,303$27.09$225K855,912Feb 27, 2026
Feb 25, 2026Bourla AlbertChairman & CEO, Directoroption exercise491,626$33.82$17M864,215Feb 27, 2026
Feb 25, 2026Bourla AlbertChairman & CEO, Directortax withholding467,241$26.92$13M388,671Feb 27, 2026
Feb 25, 2026Fonseca LidiaExecutive Vice Presidentoption exercise56,888$33.82$2M101,579Feb 27, 2026
Feb 25, 2026Fonseca LidiaExecutive Vice Presidenttax withholding1,058$27.09$29K100,521Feb 27, 2026
Feb 25, 2026Fonseca LidiaExecutive Vice Presidenttax withholding54,066$26.92$1M46,455Feb 27, 2026

Full insider history for Pfizer Inc., or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
PFIZER INC, CIK 78003 on EDGAR
Extract generated
August 27, 2026
Withheld
6 line-years whose four quarters do not sum to the filed year: cost of revenue FY2011, revenue FY2011, cost of revenue FY2012, opex sga FY2012, revenue FY2012, other income FY2013
Repaired
2 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: income tax FY2010, pretax income FY2018
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues, SalesRevenueNet
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: not filed
Research and development: not filed
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: not filed
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent, ShortTermInvestments
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated August 27, 2026.

JSON file
/data/financials/PFE.json